UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Approach to the patient with a diagnosis of atypical lymphocytic infiltrate of the skin

Author
Jeffrey Zwerner, MD
Section Editor
John A Zic, MD
Deputy Editor
Rosamaria Corona, MD, DSc

INTRODUCTION

The clinical and histologic diagnosis of cutaneous lymphoproliferative disorders is one of the most vexing issues in dermatology and dermatopathology, despite significant advances in their classification, pathogenesis, and treatment [1]. The average delay between initial presentation and the ultimate diagnosis of mycosis fungoides, the most common primary cutaneous T cell lymphoma, is six years [2]. During this period, patients typically undergo numerous skin biopsies, which, in the absence of definite histopathologic criteria for early mycosis fungoides, may be interpreted by the pathologist as "atypical lymphocytic infiltrate" or "atypical lymphocytic proliferation." This nonspecific but potentially serious diagnosis is often a source of anxiety and frustration for both the patient and the clinician.

This topic will discuss the definition of atypical lymphocytic infiltrate, the difficulties in differentiating reactive lymphocytic infiltrates from early lymphoma from the pathologist and clinician perspective, and the management of patients who receive this ambiguous diagnosis. Mycosis fungoides and other cutaneous lymphoproliferative disorders are discussed separately.

(See "Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides".)

(See "Clinical presentation, pathologic features, and diagnosis of Sézary syndrome".)

(See "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma".)

             

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Sep 30 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Cerroni L. Lymphoproliferative lesions of the skin. J Clin Pathol 2006; 59:813.
  2. Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment. Curr Probl Cancer 1990; 14:293.
  3. Cerroni L, Gatter K, Kerl H. Skin Lymphoma: The Illustrated Guide, 3rd ed, Wiley-Blackwell, Hoboken 2009.
  4. Pimpinelli N, Olsen EA, Santucci M, et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53:1053.
  5. Reddy K, Bhawan J. Histologic mimickers of mycosis fungoides: a review. J Cutan Pathol 2007; 34:519.
  6. Citarella L, Massone C, Kerl H, Cerroni L. Lichen sclerosus with histopathologic features simulating early mycosis fungoides. Am J Dermatopathol 2003; 25:463.
  7. Petit T, Cribier B, Bagot M, Wechsler J. Inflammatory vitiligo-like macules that simulate hypopigmented mycosis fungoides. Eur J Dermatol 2003; 13:410.
  8. Arai E, Shimizu M, Tsuchida T, et al. Lymphomatoid keratosis: an epidermotropic type of cutaneous lymphoid hyperplasia: clinicopathological, immunohistochemical, and molecular biological study of 6 cases. Arch Dermatol 2007; 143:53.
  9. Guitart J, Magro C. Cutaneous T-cell lymphoid dyscrasia: a unifying term for idiopathic chronic dermatoses with persistent T-cell clones. Arch Dermatol 2007; 143:921.
  10. Cerroni L, Kerl H. Diagnostic immunohistology: cutaneous lymphomas and pseudolymphomas. Semin Cutan Med Surg 1999; 18:64.
  11. Dabbs DJ. Diagnostic immunohistochemistry: theranostic and genomic applications, 3rd ed, Saunders/Elsevier, Philadelphia 2010.
  12. Florell SR, Cessna M, Lundell RB, et al. Usefulness (or lack thereof) of immunophenotyping in atypical cutaneous T-cell infiltrates. Am J Clin Pathol 2006; 125:727.
  13. Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol 2006; 33 Suppl 1:58.
  14. Plaza JA, Morrison C, Magro CM. Assessment of TCR-beta clonality in a diverse group of cutaneous T-Cell infiltrates. J Cutan Pathol 2008; 35:358.
  15. Schiller PI, Flaig MJ, Puchta U, et al. Detection of clonal T cells in lichen planus. Arch Dermatol Res 2000; 292:568.
  16. Dereure O, Levi E, Kadin ME. T-Cell clonality in pityriasis lichenoides et varioliformis acuta: a heteroduplex analysis of 20 cases. Arch Dermatol 2000; 136:1483.
  17. Shieh S, Mikkola DL, Wood GS. Differentiation and clonality of lesional lymphocytes in pityriasis lichenoides chronica. Arch Dermatol 2001; 137:305.
  18. Bergman R. Pseudolymphoma and cutaneous lymphoma: facts and controversies. Clin Dermatol 2010; 28:568.
  19. Böer A, Tirumalae R, Bresch M, Falk TM. Pseudoclonality in cutaneous pseudolymphomas: a pitfall in interpretation of rearrangement studies. Br J Dermatol 2008; 159:394.
  20. Holm N, Flaig MJ, Yazdi AS, Sander CA. The value of molecular analysis by PCR in the diagnosis of cutaneous lymphocytic infiltrates. J Cutan Pathol 2002; 29:447.
  21. Morales AV, Arber DA, Seo K, et al. Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates. Am J Dermatopathol 2008; 30:425.
  22. Cozzio A, French LE. T-cell clonality assays: how do they compare? J Invest Dermatol 2008; 128:771.
  23. van Krieken JH, Langerak AW, San Miguel JF, et al. Clonality analysis for antigen receptor genes: preliminary results from the Biomed-2 concerted action PL 96-3936. Hum Pathol 2003; 34:359.
  24. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17:2257.
  25. Langerak AW, Molina TJ, Lavender FL, et al. Polymerase chain reaction-based clonality testing in tissue samples with reactive lymphoproliferations: usefulness and pitfalls. A report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2007; 21:222.
  26. Evans PA, Pott Ch, Groenen PJ, et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2007; 21:207.
  27. Zhang B, Beck AH, Taube JM, et al. Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. J Mol Diagn 2010; 12:320.
  28. Sufficool KE, Lockwood CM, Abel HJ, et al. T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides. J Am Acad Dermatol 2015; 73:228.
  29. Thurber SE, Zhang B, Kim YH, et al. T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol 2007; 57:782.
  30. Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol 2002; 47:914.
  31. Colli C, Leinweber B, Müllegger R, et al. Borrelia burgdorferi-associated lymphocytoma cutis: clinicopathologic, immunophenotypic, and molecular study of 106 cases. J Cutan Pathol 2004; 31:232.
  32. Parry EJ, Stevens SR, Gilliam AC, et al. Management of cutaneous lymphomas using a multidisciplinary approach. Arch Dermatol 1999; 135:907.
  33. Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003; 139:857.
  34. Mougel F, Dalle S, Balme B, et al. Aggressive CD30 large cell lymphoma after cyclosporine given for putative atopic dermatitis. Dermatology 2006; 213:239.
  35. Kirby B, Owen CM, Blewitt RW, Yates VM. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. J Am Acad Dermatol 2002; 47:S165.
  36. Nakamura S, Takeda K, Hashimoto Y, et al. Primary cutaneous CD30+ lymphoproliferative disorder in an atopic dermatitis patient on cyclosporine therapy. Indian J Dermatol Venereol Leprol 2011; 77:253.